BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024
Rhea-AI Summary
BiomX Inc. (NYSE American: PHGE), a clinical-stage company developing novel natural and engineered phage therapies targeting specific pathogenic bacteria, has announced a conference call and live audio webcast scheduled for August 15, 2024, at 8:00 a.m. ET. The purpose of this event is to report the company's second quarter 2024 financial results and provide updates on its business and programs.
Interested parties can participate in the conference call by dialing 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). Additionally, a live and archived webcast will be available in the Investors section of the BiomX website at www.biomx.com.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, PHGE gained 0.56%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, August 15, 2024, at 8:00 a.m. ET, to report second quarter 2024 financial results and provide business and program updates.
To participate in the conference call, please dial 1-877-407-0724 (U.S.) or 1-201-389-0898 (International). The live and archived webcast will be available in the Investors section of the Company’s website at www.biomx.com.
About BiomX
BiomX is a clinical-stage company leading the development of natural and engineered phage cocktails and personalized phage treatments designed to target and destroy harmful bacteria for the treatment of chronic diseases with substantial unmet needs. BiomX discovers and validates proprietary bacterial targets and applies its BOLT (“BacteriOphage Lead to Treatment”) platform to customize phage compositions against these targets. For more information, please visit www.biomx.com, the content of which does not form a part of this press release.
BiomX, Inc.
Assaf Oron
+97254-2228901
assafo@biomx.com
FAQ
When will BiomX (PHGE) report its Q2 2024 financial results?
How can investors participate in BiomX's (PHGE) Q2 2024 earnings call?
What is BiomX's (PHGE) main focus as a clinical-stage company?
Where can I find the webcast for BiomX's (PHGE) Q2 2024 earnings call?
